Who owns ACRIVON THERAPEUTICS INC?
- Ticker: ACRV
- CUSIP Number: 004890109
Tip: Access positions for across all investors
Analyze quarterly positions in Acrivon Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Acrivon Therapeutics stock
Who bought or sold ACRIVON THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 12M | $22M | 47% | Jun 2026 |
|
| Sands Capital Ventures | 2.3M | $4.1M | 8% | Jun 2026 |
|
| Acadian Asset Management | 1.2M | $2.1M | 38% | Jun 2026 |
|
| Vanguard Capital Management | 952k | $1.7M | 32% | Jun 2026 |
|
| Wellington Management Company | 888k | $1.6M | 0% | Jun 2026 |
|
| Renaissance Technologies | 759k | $1.4M | 0% | Jun 2026 |
|
| Two Sigma Investments | 642k | $1.1M | 65% | Jun 2026 |
|
| Marshall Wace | 532k | $947k | -5% | Jun 2026 |
|
| Bridgeway Capital Management | 379k | $674k | 138% | Jun 2026 |
|
| Geode Capital Management | 265k | $472k | 12% | Jun 2026 |
|
| BlackRock | 239k | $426k | 14% | Jun 2026 |
|
| GSA Capital Partners | 200k | $357k | 7% | Jun 2026 |
|
| Vanguard Fiduciary Trust | 184k | $328k | 71% | Jun 2026 |
|
| XTX Topco | 178k | $317k | 166% | Jun 2026 |
|
| Jane Street | 75k | $133k | -69% | Jun 2026 |
|
| Northern Trust | 67k | $120k | 37% | Jun 2026 |
|
| State Street Corporation | 67k | $93k | 0% | Mar 2026 |
|
| UBS Group | 44k | $78k | 27% | Jun 2026 |
|
| Citadel Advisors | 41k | $74k | 100% | Jun 2026 |
|
| Morgan Stanley | 37k | $51k | -22% | Mar 2026 |
|
| Dimensional Fund Advisors | 29k | $52k | 60% | Jun 2026 |
|
| Spark Investment Management | 28k | $50k | 100% | Jun 2026 |
|
| Springbok Capital Management | 24k | $43k | 0% | Jun 2026 |
|
| Bank of America Corporation | 16k | $29k | -1% | Jun 2026 |
|
| Verdad Advisers | 15k | $27k | 100% | Jun 2026 |
|
| Goldman Sachs Group | 15k | $27k | 1% | Jun 2026 |
|
| Squarepoint Ops | 13k | $24k | -52% | Jun 2026 |
|
| AAFCPAs Wealth Management | 11k | $19k | 0% | Jun 2026 |
|
| Hrt Financial | 10k | $18k | 100% | Jun 2026 |
|
| Marex Group | 10k | $18k | -50% | Jun 2026 |
|
| Federated Investors | 7.9k | $14k | 0% | Jun 2026 |
|
| Barclays | 7.4k | $13k | 24% | Jun 2026 |
|
| FMR | 7.0k | $12k | -26% | Jun 2026 |
|
| Tower Research Capital | 1.7k | $3.0k | -63% | Jun 2026 |
|
| Crews Bank & Trust | 1.0k | $1.9k | 100% | Jun 2026 |
|
| Jpmorgan Chase & Co | 751.00 | $1.3k | 100% | Jun 2026 |
|
| NISA Investment Advisors | 584.00 | $1.0k | 0% | Jun 2026 |
|
| Bnp Paribas Arbitrage, Snc | 537.00 | $956.021100 | -15% | Jun 2026 |
|
| Redwood Park Advisors | 500.00 | $890.000000 | 0% | Jun 2026 |
|
| Russell Investments | 481.00 | $855.987600 | 0% | Jun 2026 |
|
| Federation des caisses Desjardins du Quebec | 400.00 | $712.000000 | 0% | Jun 2026 |
|
| Steward Partners Investment Advisory | 326.00 | $579.986600 | 0% | Jun 2026 |
|
| SBI Securities | 75.00 | $134.002500 | 1% | Jun 2026 |
|
| Caitong International Asset Management | 50.00 | $89.000000 | 1150% | Jun 2026 |
|
| Royal Bank of Canada | 30.00 | $0 | 20% | Jun 2026 |
|
Who sold out of Acrivon Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| PanAgora Asset Management | Mar 2026 | 34k | $47k |
| Two Sigma Securities | Mar 2026 | 12k | $16k |
| Vanguard Global Advisers | Mar 2026 | 4.5k | $6.2k |
| Wells Fargo & Company | Mar 2026 | 3.0k | $4.2k |